Cargando…

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients

BACKGROUND: To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice. METHODS: An observational, retrospective study was performed. Patients aged ≥30 years t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sicras-Mainar, Antoni, Navarro-Artieda, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342540/ https://www.ncbi.nlm.nih.gov/pubmed/25729716 http://dx.doi.org/10.4093/dmj.2015.39.1.74

Ejemplares similares

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
por: Sicras Mainar, Antoni, et al.
Publicado: (2019)

Physicians’ and patients’ opinions on the use of generic drugs
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Letter: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)
por: Seok, Hannah
Publicado: (2015)

Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Treatment profiles and costs of patients with chronic pain in the population setting
por: Mainar, Antoni Sicras, et al.
Publicado: (2012)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2019)

Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Impact on healthcare resource utilization of multiple sclerosis in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Relationship between obesity and antipsychotic drug use in the adult population: A longitudinal, retrospective claim database study in Primary Care settings
por: Sicras-Mainar, Antoni, et al.
Publicado: (2008)

Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity
por: Sicras‐Mainar, Antoni, et al.
Publicado: (2016)

Clinical validity of a population database definition of remission in patients with major depression
por: Sicras-Mainar, Antoni, et al.
Publicado: (2010)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors
por: Alanazi, Abdulrahman S.
Publicado: (2015)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2007)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
por: Sicras-Mainar, A., et al.
Publicado: (2018)

Healthcare use and costs associated with obesity in Badalona, Spain: a study protocol
por: Sicras-Mainar, Antonio, et al.
Publicado: (2012)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus
por: Fan, Yujuan, et al.
Publicado: (2015)

The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
por: Hsu, Wan-Chia, et al.
Publicado: (2022)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Adaptive capacity of the Adjusted Clinical Groups Case-Mix System to the cost of primary healthcare in Catalonia (Spain): a observational study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_iglojn6m9ur6qhieossn40bekj